Replies to post #125929 on Biotech Values

[DewDiligence]

So do I take it that your assigned probabilities to a Roche or Amgen deal is nil or close to?

That’s too strong a statement, IMO. Roche and AMGN are possible FoB partners but neither has expressed an interest in the FoB arena, so I rank them below PFE, SNY, MRK, and NVS in terms of probability.

[DewDiligence]

I agree that PFE is the most likely [FoB] partner [for MNTA]. I think they would put the FOB programs in their Established Products division (or spinoff if that were to occur).

PFE is no longer considering a spin-off of the Established Products division (#msg-64979183). It never made sense for them to do so insofar as this division is the future growth driver for the company (#msg-60933728).

That PFE plans to keep the Established Products division makes a potential FoB deal with MNTA easier to consummate than if PFE had planned to pursue a spin-off.